FDA Approved: EDARBI — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for EDARBI (azilsartan kamedoxomil) submitted by Azurity Pharmaceuticals, Inc., updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Edarbi (azilsartan medoxomil)

Snippet

SUPPL AP for EDARBI (AZILSARTAN KAMEDOXOMIL)